21,573 Pfizer Inc. $PFE Shares Sold by Kelleher Financial Advisors

Kelleher Financial Advisors trimmed its stake in Pfizer Inc. (NYSE:PFE) by 42.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 29,536 shares of the biopharmaceutical company’s stock after selling 21,573 shares during the period. Kelleher Financial Advisors’ holdings in Pfizer were worth $842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Retirement Wealth Solutions LLC lifted its stake in shares of Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 509 shares during the period. Keb Asset Management LLC bought a new position in Pfizer during the second quarter valued at about $26,000. Field & Main Bank acquired a new position in Pfizer in the 2nd quarter valued at approximately $27,000. Bullseye Investment Management LLC acquired a new position in Pfizer in the 2nd quarter valued at approximately $28,000. Finally, Timbuktu Capital Management LLC acquired a new position in Pfizer in the 2nd quarter valued at approximately $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 2.6%

Shares of NYSE PFE opened at $30.79 on Thursday. The stock has a market cap of $175.52 billion, a PE ratio of 43.99, a PEG ratio of 2.04 and a beta of 0.31. The business has a fifty day moving average of $28.69 and a two-hundred day moving average of $26.86. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $31.06. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.13. The business had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a net margin of 6.34% and a return on equity of 19.98%. The firm’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.87 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.6%. Pfizer’s payout ratio is 226.32%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Argus set a $40.00 price objective on Pfizer in a research report on Wednesday. UBS Group upped their target price on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Wednesday. HSBC raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. Finally, Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $29.81.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised its 2026 revenue outlook to $62–$64 billion and adjusted EPS forecast to $2.95–$3.05, citing execution and cost savings. Reuters article
• Positive Sentiment: Growth in newer and acquired medicines is helping offset pandemic-product declines: these products grew 32% operationally in Q3, while non-COVID products overall grew 7%. This supports Pfizer’s effort to build growth beyond COVID sales. The Motley Fool article
• Positive Sentiment: Scotiabank raised its price target to $35 and maintained a “sector outperform” rating, signaling further potential upside. Ticker Report article
• Neutral Sentiment: Pfizer named Cecile Guegan permanent CFO after she served in the interim role. The appointment provides leadership continuity, though its near-term financial impact is unclear. Business Wire announcement
• Negative Sentiment: COVID-related product sales continued to decline, and revenue was slightly lower year over year. UBS and Citi raised their targets to $30 and RBC to $28, but each retained a neutral or sector-perform rating—targets below the recent share price that may temper expectations. UBS rating

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.